LDS/Medical Tests/Creatine Kinase (CK)

Creatine Kinase (CK)

Creatine kinase (CK) is an enzyme found in heart, brain, skeletal muscle and other tissues that catalyze the reversible phosphorylation of creatine by ATP. The end product, phosphocreatine, is a readily available energy source for cells. Therefore, this enzyme is present in every cell; however, highly concentrated levels of this enzyme are seen in skeletal muscle, heart muscle, smooth muscle, and brain. The CK enzyme is a dimer protein composed of subunits derived from either muscle (M) or brain (B). Based on a combination of these two subunits, three isoenzymes have been identified: MM, MB, and BB. Normal serum CK is predominantly the CK-MM isoenzyme. Elevated CK-serum levels are found in skeletal muscle disease, particularly muscular dystrophies and muscle damage (trauma). The CK-MB fraction is found primarily in myocardial tissue and its presence is generally detected within the 48-hour period following the onset of a myocardial infarction. The use of total CK and CK-MB in the diagnosis of myocardial infarction is the most important single application of CK measurement in clinical diagnostics. Serum CK activity is also increased after cerebral ischemia, acute cerebrovascular injury and head injury.

Testing for CK is helpful in diagnosing other muscle related diseases such as rhabdomyolysis, which is characterized by skeletal muscle damage and loss. In addition, increased levels of CK are seen in neuromuscular degenerative disorders such as muscular dystrophies and polymyositis/dermatomyositis, but not to the same extent as rhabdomyolysis. Slightly elevated levels of CK are also seen in muscle trauma (damage) and burns where muscle cells are damaged or destroyed.

  • In diagnosis of acute myocardial infarction
  • In diagnosis of rhabdomyolysis
  • In diagnosis of muscular dystrophies (e.g., Duchenne and Becker)
  • In diagnosis of polymyositis/dermatomyositis
  • As an aid in diagnosis and differentiation of muscular disease versus muscle trauma (muscle damage)

Increased in:

  • Myocardial infarction
  • Rhabdomyolysis
  • Muscular dystrophy (e.g., Duchenne and Becker)
  • Polymyositis
  • Also increased in myocarditis
  • Sever muscle trauma (muscle damage)
  • Severe muscular exertion
  • Cerebral infarction/damage
  • Reye syndrome
  • Elevated levels are seen in individuals using drugs such as clofibrate and HMG-CoA reductase inhibitors

32 – 267 U/L (0.53 – 4.45 mckat/L)
 

 

Enzymatic, kinetic spectrophotometric

Serum (SST) or Plasma Heparin (Green). 

Stability

  • Ambient: 3-5 days
  • Refrigerated: 5-7 days
  • Frozen: 30 days
Serial measurement of CK activity at 0, 6, and 12 hours after the onset of chest pain yields the greatest sensitivity and specificity, especially if tested with CK-MB. Total CK is not specific enough for use in diagnosis of MI, but a normal total CK has a high negative predictive value. Additional testing include; CK Isoenzymes, Myoglobin, Troponin, LD (LDH), Myotonic Dystrophy DNA Test, Duchenne/Becker Muscular Dystrophy DNA test.
Same day.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Clin Chem. 1980 Aug;26(9):1241-50. [PMID: 6994925]
  • Surg Clin North Am. 1985 Jun;65(3):539-51. [PMID: 3898430]
  • Prog Cardiovasc Dis. 2004;46:404. [PMID: 15179629]
  • Crit Care. 2005;9:158. [PMID: 15774072]
  • Curr Rheumatol Rep. 2006;8:178. [PMID: 16901075] J Magn Reson Imaging. 2011 Apr;33(4):847-54. doi: 10.1002/jmri.22491. [PMID: 21448949]
  • Alan Wu. Tietz Clinical Guide to Laboratory Tests, Fourth Edition. Saunders; 4 edition (June 13, 2006). ISBN-10: 0721679757